Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Meiragtx Holdings Plc (NQ: MGTX ) 6.220 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Meiragtx Holdings Plc < Previous 1 2 3 Next > Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session October 30, 2023 Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. Via Benzinga Why Is Gene Therapy Company MeiraGTx Stock Trading Higher Today? October 30, 2023 MeiraGTx Holdings plc (NASDAQ: MGTX) shares are trading higher after French pharma giant Sanofi SA (NASDAQ: SNY) made a $30 million Via Benzinga MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities October 30, 2023 From MeiraGTx Via GlobeNewswire MeiraGTx Hldgs: Q1 Earnings Insights May 11, 2023 Via Benzinga MeiraGTx Holdings's Return On Capital Employed Overview March 15, 2023 Via Benzinga MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms December 13, 2022 Via Benzinga MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress October 24, 2023 Multiple Posters and Oral Presentations Highlight the Depth of Innovation from MeiraGTx’s Technology Platforms for Gene and Cell Therapy From MeiraGTx Via GlobeNewswire MeiraGTx Reports Second Quarter 2023 Financial and Operational Results August 10, 2023 From MeiraGTx Via GlobeNewswire MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology August 01, 2023 RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapy From MeiraGTx Via GlobeNewswire MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing July 19, 2023 From MeiraGTx Via GlobeNewswire MeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness June 27, 2023 MeiraGTx Holdings plc (NASDAQ: MGTX) released data from the completed Phase 1 AQUAx study of AAV2-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX), which includes the final 12-month data from... Via Benzinga MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia June 27, 2023 From MeiraGTx Via GlobeNewswire MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, June 22, 2023 From MeiraGTx Via GlobeNewswire Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying May 16, 2023 Although US stocks closed higher on Monday, there were a few notable insider trades. Via Benzinga MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting May 16, 2023 Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy From MeiraGTx Via GlobeNewswire MeiraGTx Reports First Quarter 2023 Financial and Operational Results May 11, 2023 From MeiraGTx Via GlobeNewswire MeiraGTx Announces $60 Million Private Placement of Ordinary Shares May 03, 2023 From MeiraGTx Via GlobeNewswire MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting April 21, 2023 From MeiraGTx Via GlobeNewswire MeiraGTx to Participate in Upcoming Investor Conferences April 20, 2023 From MeiraGTx Via GlobeNewswire MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results March 14, 2023 From MeiraGTx Via GlobeNewswire MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia December 13, 2022 From MeiraGTx Via GlobeNewswire MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022 December 08, 2022 From MeiraGTx Via GlobeNewswire MeiraGTx to Participate in Upcoming Investor Conferences November 22, 2022 From MeiraGTx Via GlobeNewswire Stocks That Hit 52-Week Lows On Thursday November 10, 2022 During Thursday's session, 97 companies made new 52-week lows. Via Benzinga MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc. November 10, 2022 From MeiraGTx Via GlobeNewswire MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress October 04, 2022 Multiple Poster Presentations Highlight Versatility and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy From MeiraGTx Via GlobeNewswire Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP) October 01, 2022 Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which... From MeiraGTx Via GlobeNewswire Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness September 29, 2022 Kiora Pharmaceuticals Inc. (NASDAQ: KPRX), a pharmaceutical company specializing in treating eye diseases, is moving its drug candidate KIO-301 into a Phase 1b study in the third quarter of this year. Via Benzinga Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session August 03, 2022 Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. Via Benzinga This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday August 04, 2022 Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
